Klick Health Launches First AI Social Media Comment Moderator for Life Sciences Industry

KCM+AI provides pharma brands with enhanced handling of pharmacovigilance issues via 24/7 monitoring and automatic comment-holding

Klick Health launched Klick Comment Moderator+AI (KCM+AI), the life sciences industry’s first social media comment moderator powered by artificial intelligence. KCM+AI is powered by Microsoft Azure AI and a proprietary Klick model trained on almost 400,000 historical comments to enhance pharmacovigilance (PV) detection and reporting and make community management more efficient and interactive.

“We see KCM+AI as a digital assistant that keeps our clients’ brands more protected from pharmacovigilance issues, while enabling our community managers to focus on higher-level work, such as social strategy and complex questions asked of the brand.”

The release of KCM+AI marks the next generation of Klick Comment Moderator (KCM), introduced in 2015 to provide brand safety in the highly regulated industry by holding social media comments for review. For almost a decade, KCM has been keeping clients safe in many therapeutic areas, including immunology and neurology. KCM was used in the award-winning Lighter Blue social media initiative, which had over one million Facebook followers and 10 million engagements, and opened dialogue about major depressive disorder symptoms.

Recommended AI News: Session AI Announces World’s First Solution for Real-Time AI Incentive Optimization

The agency updated the tool with AI to provide real-time, round-the-clock PV protection through the detection of adverse events and product complaints with over 95 percent accuracy. KCM+AI automatically flags and hides comments for moderation to Klick’s community managers and routes those requiring responses to Klick’s Science & Regulatory team. It also incorporates language transparency to help manage brands’ social pages across different languages.

“We’ve trusted Klick’s KCM for years to ensure our social media engagement is both safe and compliant, and the leap to KCM+AI brings exciting prospects,” said Acorda Therapeutics Executive Director, Digital Strategy & Development Rich Muser.

Added Acorda’s Vice President of Digital Strategy and Innovation Michael Russo, “Its advanced AI capabilities promise to revolutionize pharmacovigilance with efficiency and smarter moderation, something pharma is eager to embrace.”

Recommended AI News: Broadcom Extends Technology and Volume Leadership on AI Optical Components

Klick’s Senior Vice President, Strategic Futures Brad Einarsen said, “We see KCM+AI as a digital assistant that keeps our clients’ brands more protected from pharmacovigilance issues, while enabling our community managers to focus on higher-level work, such as social strategy and complex questions asked of the brand.”

KCM+AI is available to all Klick clients. It is currently supported on Meta (Instagram and Facebook) and will provide coverage on additional social platforms in the near future.

Today’s announcement is the latest in the company’s ongoing AI and machine-learning innovations created to help Klicksters and Klick clients elevate outcomes. In December, the agency announced the $1 million Klick P**** for Klicksters with game-changing AI ideas for clients; and, at the prestigious NeurIPS conference, it unveiled LOVENet, an AI framework that rapidly identifies new uses for existing drugs. In November, it introduced Genome Perspective, the first AI tool to be developed by an advertising agency to expedite project planning and increase the efficiency and velocity of delivery to clients; and, in September, it launched KlickRx, the first ChatGPT plugin for the life sciences industry in the U.S.

Recommended AI News: NoTraffic Expands its Operations and Launches in the State of Florida

[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]